[1] DENYER A L, CATCHPOLE B, DAVISON L J, et al. Genetics of canine diabetes mellitus part 1:phenotypes of disease[J]. Vet J, 2021, 270:105611. [2] HULSEBOSCH S E, PIRES J, BANNASCH M J, et al. Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs[J]. J Vet Intern Med, 2022, 36(4):1211-1219. [3] MILLER E J, BRINES C M. Canine diabetes mellitus associated ocular disease[J]. Top Companion Anim Med, 2018, 33(1):29-34. [4] NIAZ K, MAQBOOL F, KHAN F, et al. Comparative occurrence of diabetes in canine, feline, and few wild animals and their association with pancreatic diseases and ketoacidosis with therapeutic approach[J]. Vet World, 2018, 11(4):410-422. [5] MOSHREF M, TANGEY B, GILOR C, et al. Concise review:canine diabetes mellitus as a translational model for innovative regenerative medicine approaches[J]. Stem Cells Transl Med, 2019, 8(5):450-455. [6] NELSON R W, REUSCH C E. Animal models of disease:classification and etiology of diabetes in dogs and cats[J]. J Endocrinol, 2014, 222(3):T1-T9. [7] CATCHPOLE B, KENNEDY L J, DAVISON L J, et al. Canine diabetes mellitus:from phenotype to genotype[J]. J Small Anim Pract, 2008, 49(1):4-10. [8] FISHER F M, MARATOS-FLIER E. Understanding the physiology of FGF21[J]. Annu Rev Physiol, 2016, 78:223-241. [9] ANDERSEN B, OMAR B A, RAKIPOVSKI G, et al. Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes[J]. Eur J Pharmacol, 2015, 764:189-194. [10] KIM H W, LEE J E, CHA J J, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice[J]. Endocrinology, 2013, 154(9):3366-3376. [11] ZHANG J, WENG W Y, WANG K, et al. The role of FGF21 in type 1 diabetes and its complications[J]. Int J Biol Sci, 2018, 14(9):1000-1011. [12] XU P F, ZHANG Y J, JIANG X H, et al. Canine fibroblast growth factor 21 ameliorates hyperglycemia associated with inhibiting hepatic gluconeogenesis and improving pancreatic beta-cell survival in diabetic mice and dogs[J]. PLoS One, 2016, 11(5):e0155598. [13] KHARITONENKOV A, WROBLEWSKI V J, KOESTER A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21[J]. Endocrinology, 2007, 148(2):774-781. [14] MAACK T, JOHNSON V, KAU S T, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins:a review[J]. Kidney Int, 1979, 16(3):251-270. [15] KRISTENSEN M, BIRCH D, NIELSEN H M. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos[J]. Int J Mol Sci, 2016, 17(2):185. [16] GAUTAM A, SINGH H, TYAGI A, et al. CPPsite:a curated database of cell penetrating peptides[J]. Database (Oxford), 2012, 2012:bas015. [17] FUTAKI S, SUZUKI T, OHASHI W, et al. Arginine-rich peptides:an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery[J]. J Biol Chem, 2001, 276(8):5836-5840. [18] DUIVELSHOF B L, MURISIER A, CAMPERI J, et al. Therapeutic Fc-fusion proteins:current analytical strategies[J]. J Sep Sci, 2021, 44(1):35-62. [19] CHEN Y, WANG J J, LI J, et al. Activating transcription factor 4 mediates hyperglycaemia-induced endothelial inflammation and retinal vascular leakage through activation of STAT3 in a mouse model of type 1 diabetes[J]. Diabetologia, 2012, 55(9):2533-2545. [20] HOENIG M. Comparative aspects of diabetes mellitus in dogs and cats[J]. Mol Cell Endocrinol, 2002, 197(1-2):221-229. [21] ADAMS J P, HOLDER A L, CATCHPOLE B. Recombinant canine single chain insulin analogues:insulin receptor binding capacity and ability to stimulate glucose uptake[J]. Vet J, 2014, 202(3):436-442. [22] PETKOVA S B, AKILESH S, SPROULE T J, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model:potential application in humorally mediated autoimmune disease[J]. Int Immunol, 2006, 18(12):1759-1769. [23] SUHORUTSENKO J, OSKOLKOV N, ARUKUUSK P, et al. Cell-penetrating peptides, pepfects, show no evidence of toxicity and immunogenicity in vitro and in vivo[J]. Bioconjugate Chem, 2011, 22(11):2255-2262. [24] FLIPPO K H, POTTHOFF M J. Metabolic messengers:FGF21[J]. Nat Metab, 2021, 3(3):309-317. [25] MICANOVIC R, RACHES D W, DUNBAR J D, et al. Different roles of N-and C-termini in the functional activity of FGF21[J]. J Cell Physiol, 2009, 219(2):227-234. [26] JIANG S Z, YOUNG J L, WANG K, et al. Diabetic-induced alterations in hepatic glucose and lipid metabolism:the role of type 1 and type 2 diabetes mellitus (Review)[J]. Mol Med Rep, 2020, 22(2):603-611. [27] RUI L Y. Energy metabolism in the liver[J]. Compr Physiol, 2014, 4(1):177-197. [28] GE X, CHEN C, HUI X Y, et al. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/ets-like protein-1 in adipocytes[J]. J Biol Chem, 2011, 286(40):34533-34541. [29] KANWAL A, SINGH S P, GROVER P, et al. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2[J]. Anal Biochem, 2012, 429(1):70-75. [30] WADWA R P, KINNEY G L, MAAHS D M, et al. Awareness and treatment of dyslipidemia in young adults with type 1 diabetes[J]. Diabetes Care, 2005, 28(5):1051-1056. [31] BELL D S H, ALLBRIGHT E. The multifaceted associations of hepatobiliary disease and diabetes[J]. Endocr Pract, 2007, 13(3):300-312. [32] GOODARZI M T, NAVIDI A A, REZAEI M, et al. Oxidative damage to DNA and lipids:correlation with protein glycation in patients with type 1 diabetes[J]. J Clin Lab Anal, 2010, 24(2):72-76. [LL] [33] ZECHNER D, SPITZNER M, BOBROWSKI A, et al. Diabetes aggravates acute pancreatitis and inhibits pancreas regeneration in mice[J]. Diabetologia, 2012, 55(5):1526-1534. [34] CNOP M, HAVEL P J, UTZSCHNEIDER K M, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins:evidence for independent roles of age and sex[J]. Diabetologia, 2003, 46(4):459-469. [35] LEIN M, DERONDE B M, SGOLASTRA F, et al. Protein transport across membranes:comparison between lysine and guanidinium-rich carriers[J]. Biochim Biophys Acta (BBA)-Biomembr, 2015, 1848(11):2980-2984. [36] MADANI F, LINDBERG S, LANGEL U, et al. Mechanisms of cellular uptake of cell-penetrating peptides[J]. J Biophys, 2011, 2011:414729. [37] KLIEWER S A, MANGELSDORF D J. A dozen years of discovery:insights into the physiology and pharmacology of FGF21[J]. Cell Metab, 2019, 29(2):246-253. |